What does the FDA approval of Merck’s Welireg-Keytruda combo mean for early kidney cancer?

The FDA cleared Merck’s Welireg and Keytruda combination for adjuvant treatment of early-stage renal cell carcinoma, expanding Welireg’s prior use in advanced disease. The move strengthens Merck’s oncology portfolio ahead of Keytruda’s patent expiry and signals a strategic shift toward earlier immunotherapy use without new financial deals.